Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 82 of 116

  1. temozolomide

    Children's Hospital of Fudan University

    Brain and Central Nervous System Tumors

    phase 2 small molecule completed

    1 trial

  2. the standard "3+7" regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Newly Diagnosed Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  3. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial

  4. tisotumab vedotin

    Genmab A/S

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  5. toripalimab

    The First People's Hospital of Lianyungang

    Malignant Melanoma

    phase 2 small molecule active

    1 trial

  6. trifluridine/tipiracil combined with fufuquitinib

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  7. troxacitabine

    Takeda

    Leukemia

    phase 2 small molecule completed

    1 trial

  8. vidutolimod

    Regeneron UK Limited

    Merkel Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  9. vilastobart (XTX101)

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  10. vinflunine

    Bristol-Myers Squibb

    Transitional Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  11. vistusertib (AZD2014)

    Samsung Bioepis NL B.V.

    Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  12. vitamin C

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  13. vitamin C

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  14. volrustomig, Monalizumab

    Pari Pharma GmbH

    cancerology

    phase 2 small molecule active

    1 trial

  15. ​​D798VC00001​

    AstraZeneca AB

    ​​Colorectal cancer​

    phase 2 small molecule active

    1 trial

  16. 0439-24

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 1 other active

    1 trial

  17. 1 mg/kg GR-MD-02

    GALECTIN THERAPEUTICS INC

    Metastatic Melanoma

    phase 1 mab completed

    1 trial

  18. 1230.15

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  19. 1403-0001

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  20. 1403-0002

    Boehringer Ingelheim

    advanced solid tumors

    phase 1 other active

    1 trial

  21. 1403-0004

    Boehringer Ingelheim

    Solid cancer tumors

    phase 1 other active

    1 trial

  22. 1438-0001

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  23. 1438-0007

    Boehringer Ingelheim

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  24. 1438-0008

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  25. 1438-0009

    Boehringer Ingelheim

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  26. 1443-0002

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  27. 1443-0003

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  28. 145 mg/m2 NKTR 102

    Nektar Therapeutics UK Limited

    Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  29. 1454-0015

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  30. 1456-0001

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  31. 1463-0001

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  32. 1479-0001

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  33. 1501-0002

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  34. 1505-0001

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 other active

    1 trial

  35. 1527-0001

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  36. 1538-0001

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  37. 17651

    Disc Medicine

    Locally advanced rectal cancer

    phase 1 other active

    1 trial

  38. 177Lu-DOTA-TLX591

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 mab completed

    1 trial

  39. 177Lu-TLX250 and Peposertib

    Telix Innovations

    Solid Tumor, Adult

    phase 1 other active

    1 trial

  40. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  41. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  42. 18F-PEG6-IPQA

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 1 small molecule completed

    1 trial

  43. 19(T2)28z1xx CAR T cells

    Takeda

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule active

    1 trial

  44. 19(T2)28z1xx TRAC T cell

    Takeda

    B-Cell Lymphoma

    phase 1 mab active

    1 trial

  45. 20 mg/kg TRU-016 + Rituximab

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  46. 2001-0001

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  47. 2012-0001

    Boehringer Ingelheim

    unresectable advanced or metastatic solid cancer

    phase 1 other active

    1 trial

  48. 20160323

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.